Accelerate Diagnostics Inc. (AXDX) Trading Down 3.5%
Accelerate Diagnostics Inc. (NASDAQ:AXDX) shares traded down 3.5% on Monday . The stock traded as low as $19.37 and last traded at $19.71, with a volume of 170,403 shares. The stock had previously closed at $20.43.
Several research analysts have recently weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $26.00 price objective on shares of Accelerate Diagnostics in a report on Sunday, May 15th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $25.00 price objective on shares of Accelerate Diagnostics in a report on Monday, May 16th. Finally, Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Accelerate Diagnostics has a consensus rating of “Buy” and a consensus price target of $22.67.
The company’s 50-day moving average is $16.46 and its 200-day moving average is $14.09. The firm’s market cap is $1.01 billion.
In related news, Director Jack W. Schuler bought 11,511 shares of the company’s stock in a transaction on Monday, May 16th. The shares were purchased at an average price of $11.91 per share, for a total transaction of $137,096.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jack W. Schuler bought 90,147 shares of the company’s stock in a transaction on Thursday, June 30th. The shares were bought at an average price of $13.95 per share, for a total transaction of $1,257,550.65. The disclosure for this purchase can be found here.
An institutional investor recently raised its position in Accelerate Diagnostics stock. Neuberger Berman Group LLC increased its stake in Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 124.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,500 shares of the company’s stock after buying an additional 26,850 shares during the period. Neuberger Berman Group LLC owned approximately 0.11% of Accelerate Diagnostics worth $1,042,000 as of its most recent SEC filing.
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.